Femasys (FEMY) Competitors $0.63 +0.22 (+51.87%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$0.81 +0.18 (+28.39%) As of 09:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FEMY vs. SLNO, NMTC, ZYXI, CLGN, MODD, ECOR, MLSS, POCI, RBOT, and STRRShould you be buying Femasys stock or one of its competitors? The main competitors of Femasys include Soleno Therapeutics (SLNO), NeuroOne Medical Technologies (NMTC), Zynex (ZYXI), CollPlant Biotechnologies (CLGN), Modular Medical (MODD), electroCore (ECOR), Milestone Scientific (MLSS), Precision Optics (POCI), Vicarious Surgical (RBOT), and Star Equity (STRR). These companies are all part of the "medical equipment" industry. Femasys vs. Its Competitors Soleno Therapeutics NeuroOne Medical Technologies Zynex CollPlant Biotechnologies Modular Medical electroCore Milestone Scientific Precision Optics Vicarious Surgical Star Equity Femasys (NASDAQ:FEMY) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends. Which has higher valuation and earnings, FEMY or SLNO? Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFemasys$1.89M10.88-$18.82M-$0.86-0.73Soleno TherapeuticsN/AN/A-$175.85M-$4.14-14.30 Is FEMY or SLNO more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,113.72%. Soleno Therapeutics' return on equity of -73.74% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Femasys-1,113.72% -713.74% -152.60% Soleno Therapeutics N/A -73.74%-56.67% Does the media favor FEMY or SLNO? In the previous week, Soleno Therapeutics had 6 more articles in the media than Femasys. MarketBeat recorded 7 mentions for Soleno Therapeutics and 1 mentions for Femasys. Femasys' average media sentiment score of 0.00 equaled Soleno Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Soleno Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, FEMY or SLNO? Femasys has a beta of -2.64, indicating that its stock price is 364% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.75, indicating that its stock price is 375% less volatile than the S&P 500. Do analysts recommend FEMY or SLNO? Femasys presently has a consensus price target of $7.33, indicating a potential upside of 1,063.84%. Soleno Therapeutics has a consensus price target of $115.09, indicating a potential upside of 94.38%. Given Femasys' higher possible upside, analysts clearly believe Femasys is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Soleno Therapeutics 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.92 Do institutionals and insiders hold more shares of FEMY or SLNO? 65.3% of Femasys shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 11.5% of Femasys shares are held by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummarySoleno Therapeutics beats Femasys on 8 of the 15 factors compared between the two stocks. Get Femasys News Delivered to You Automatically Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FEMY vs. The Competition Export to ExcelMetricFemasysMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.53M$3.35B$6.11B$10.54BDividend YieldN/A2.28%5.66%4.70%P/E Ratio-0.7322.2886.8626.71Price / Sales10.88265.33534.62203.40Price / CashN/A46.3226.3031.11Price / Book6.309.9012.796.58Net Income-$18.82M-$52.45M$3.30B$276.25M7 Day Performance79.01%5.05%3.52%1.96%1 Month Performance67.62%10.61%6.75%9.12%1 Year Performance-43.23%25.03%73.76%31.61% Femasys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FEMYFemasys2.5812 of 5 stars$0.63+51.9%$7.33+1,063.8%-43.2%$20.53M$1.89M-0.7330Analyst UpgradeGap UpHigh Trading VolumeSLNOSoleno Therapeutics4.1753 of 5 stars$68.16+4.9%$115.09+68.9%+19.3%$3.45BN/A-16.4630NMTCNeuroOne Medical Technologies2.7921 of 5 stars$0.90-2.1%$2.23+147.2%-3.0%$45.95M$3.45M-6.0020Analyst UpgradeGap UpZYXIZynex2.3143 of 5 stars$1.47+1.4%$4.90+233.3%-81.4%$43.93M$192.35M-1.56770CLGNCollPlant Biotechnologies2.3987 of 5 stars$2.90-7.6%$11.50+296.6%-50.1%$39.93M$510K-2.5770Gap UpMODDModular Medical0.4196 of 5 stars$0.70-0.6%N/A-70.4%$38.92MN/A-1.3720ECORelectroCore2.4041 of 5 stars$4.90-0.6%$25.50+420.4%-31.8%$37.39M$25.18M-3.0250Gap UpMLSSMilestone Scientific2.9006 of 5 stars$0.46-0.8%$1.25+174.1%-50.2%$36.14M$9.08M-6.5130POCIPrecision Optics0.7248 of 5 stars$4.39flatN/A-8.1%$33.66M$17.63M-4.9380Earnings ReportHigh Trading VolumeRBOTVicarious Surgical0.7335 of 5 stars$5.42-0.8%$7.00+29.3%+24.3%$32.38MN/A-0.54210STRRStar Equity1.1846 of 5 stars$11.16-2.1%$5.00-55.2%+186.7%$31.41M$140.06M-8.581,300Gap Up Related Companies and Tools Related Companies Soleno Therapeutics Alternatives NeuroOne Medical Technologies Alternatives Zynex Alternatives CollPlant Biotechnologies Alternatives Modular Medical Alternatives electroCore Alternatives Milestone Scientific Alternatives Precision Optics Alternatives Vicarious Surgical Alternatives Star Equity Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FEMY) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
